Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension Study
NCT00947037 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2015-11-24
Summary
An extension of study IN 09 004 testing the long term safety of the Accordion Pill Carbidopa/Levodopa (AP-CD/LD)
Conditions
Interventions
- DRUG
-
AP-CD/LD
Sponsors & Collaborators
-
Intec Pharma Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 30 Years
- Max Age
- 95 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-08-31
- Primary Completion
- 2012-08-31
Countries
- Israel
Study Locations
More Related Trials
-
Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease
NCT00219284 ·Status: COMPLETED ·Phase: PHASE4
-
Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in Healthy Chinese Subjects
NCT05976737 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease
NCT05036473 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon
NCT01568073 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.
NCT03496870 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease
NCT00558337 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
NCT00286897 ·Status: COMPLETED ·Phase: PHASE3
-
A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)
NCT02486432 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)
NCT02807675 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes
NCT01617135 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
NCT02170376 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
NCT00360308 ·Status: TERMINATED ·Phase: PHASE3
-
Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions
NCT05128175 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations
NCT03670953 ·Status: COMPLETED ·Phase: PHASE3
-
Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients
NCT02763137 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
NCT00357994 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of E2007 In Patients With Parkinson's Disease
NCT00427011 ·Status: TERMINATED ·Phase: PHASE2
-
Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off
NCT00601978 ·Status: WITHDRAWN ·Phase: PHASE4
-
Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects
NCT00360568 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants
NCT02337751 ·Status: COMPLETED ·Phase: PHASE3
-
Study of LY300164 for the Treatment of Parkinson's Disease
NCT00004576 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
NCT02469090 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants
NCT02337738 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Randomized Safety Study of CVT-301 Compared to an Observational Control Group
NCT02352363 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD
NCT04821687 ·Status: COMPLETED ·Phase: PHASE4